Few studies have observed the high incidence of thrombocytopenia after suture-less Perceval valve implantation [1] - [6]. However, the time course of decline and recovery has not been fully reported previously. In addition, the impact of this thrombocytopenia on clinical outcomes is not clear. As such, we have examined our experience with both suture-less Perceval valve and sutured bioprosthetic valve (Magna) on the platelets count and correlated that with clinical outcomes.

Our cohort consisted of 70 patients (42 patients with Perceval suture-less valve and 28 patients with Magna bioprosthetic valve). Age ranged from 17 to 82 years old with mean (± SD) of 56.1 ± 15.6. There were 35 females and 35 males (50% each). There was one in hospital death in the whole cohort in the Perceval group (1.4% mortality due to pneumonia and sepsis). Preoperative factors and patients’ characteristics are summarized in Table 1. As shown in this table, the two groups were similar in most baseline characteristics with the exception of age, hyperlipidemia and ejection fraction. Patients receiving Magna valve were on average 10 years younger compared to those receiving Perceval valve with lower incidence of dyslipidemia and lower ejection fraction. As expected, aortic cross clamp time and cardiopulmonary bypass time were both significantly shorter in the suture-less Perceval group compared to the sutured Magna valve group reflecting the difference in the implantation technique [9].

Table 2 shows the platelet count and mean platelet volume between the two groups. As shown, the mean platelets count at baseline was similar in the two valve groups. However, by day 1 onwards until day 7, the mean platelet counts were significantly lower in the suture-less Perceval valve group than in the Magna

SD: standard deviation. N/S: not significant. COPD: chronic obstructive pulmonary disease. CPB: cardiopulmonary bypass.

N/S: not significant.

sutured valve group. This effect is also shown in Figure 1(A), where the platelet count dropped significantly until day 3 postoperative and then slowly increased until day 7 and returned to normal levels in follow up period (2 weeks post- operative). In the Magna group, platelet count dropped slightly by day 1 and then remain at plateau until day 4 where they started to increase towards baseline by day 7 and became higher than baseline at follow-up (Figure 1(B)). Mean platelet volume (MPV) was not different between the two groups in most of the time points collected and remained around the level of baseline values. By examining the time curves of MPV in both groups, they remained around the baseline value (Figure 2(A) and Figure 2(B)).

In hospital mortality was similar between the two groups (Table 3). In addition, the rate of blood product transfusion (especially platelets) and rate of re-exploration for bleeding were similar between the two types of valves. The postoperative complications were also similar between the two groups. As shown in the table, suture-less Perceval group had significantly shorter intensive care unit and hospital stay compared to the Magna valve. The observed thrombocytopenia in the Perceval valve group had no effect on the rate of postoperative complications when compared to the Magna bioprosthetic valve.

One of the proposed advantages of the suture-less valves is lack of sewing ring

SD: standard deviation. N/S: not significant. ICU: intensive care unit.

resulting in the implantation of larger size valve and potentially improving valve hemodynamics [7] [8] [10]. In addition, both aortic cross clamp time and cardiopulmonary bypass time are significantly shorter in the suture-less valves compared to the conventional sutured valve resulting in a potential advantage in terms of postoperative complications as we had previously reported [11]. However, there is an increased risk of permanent pacemaker insertion associated with the use of suture-less valves compared to the conventional valves as reported in a recent meta-analysis [12]. The observation of postoperative thrombocytopenia in the Perceval valve remains a concern and its effect and time course are not well understood.

Our data are consistent with a study reported previously [4]. In that study, the authors had observed a decline of platelet count in suture-less Perceval valve until day 3 with a slight increase by day 5 postoperative and mild improvement at discharge but never reached preoperative levels. Mean platelet volume (MPV) showed significantly increased values in the Perceval vs Intuity suture-less valves post-operatively. However, careful examination of their data also showed that the MPV values of the Perceval subgroup were similar to the baseline preoperative values (as we showed in our study). In addition, they showed by using multivariate analysis that Perceval valve was as independently associated with postoperative thrombocytopenia (compared to Intuity sutures less valve). They also reported that at 1 year the platelet count was not significantly different from preoperative values in the Perceval suture-less valve. Our data were also consistent with another report [5]. In their work, thrombocytopenia was also observed post operatively in Perceval valve recipients more than Magna valve recipients. The maximal decline was at day 3 postoperatively with gradual increase from day 4 onwards but still not reaching the baseline on day 7 postoperatively. They also showed no difference in major complications postoperatively among type of valve used although their platelet transfusion was significantly higher in Perceval group when compared to Magna bioprosthetic group.

The observed thrombocytopenia in the postoperative period following Perceval suture-less valve implantation could be a transient direct toxic effects of these valves on platelets caused by the storage solutions used or the micro hemodynamic effects of the prosthetic structure. It has been reported that the anti-calcification treatment with Homocysteic acid (HCA) was the underlying mechanism for thrombocytopenia associated with Sorin valve (including Sorin S Perceval valve) [2]. Our data does correlate with the thrombocytopenia that is observed with Perceval valve and shows that it is a temporary phenomenon with return to normal counts 2 weeks’ post-operative. In addition, lack of correlation between the post-operative outcome and the type of valve used show that the thrombocytopenia is a benign phenomenon.

Although our data were prospectively enrolled in the departmental database, the analysis was a retrospective design which only can raise association rather than casualty. In addition, our sample size of isolated aortic valve surgery enrolled was small (70 patients total). Another limitation is that the platelet counts, and mean platelet volume were measured based on the clinical situation and not consistently in the same exact time points in all patients. However, within these limitations, we believe that our work will shed more light on the observation of thrombocytopenia following Perceval valve implantation and can stimulate more research into the subject.

Thrombocytopenia occurs following Perceval valve implantation and it is a transient phenomenon with improvement after 3 days post-surgery and full recovery within 2 weeks of surgery. This observation does not seem to have an effect on the postoperative outcomes of patients receiving Perceval valve. This phenomenon is not seen to that extent in the sutured bioprosthetic valve and may be due to the design or the preservation method used in the Perceval valve.

The authors declare no conflicts of interest regarding the publication of this paper.

Al-Sarraf, N., Esmaeil, H., Samani, S., Almaie, M., Abdelsalam, A. and Al-Fadhli, J. (2022) Thrombocytopenia Following Perceval Suture-Less Aortic Valve Implantation. World Journal of Cardiovascular Surgery, 12, 119-127. https://doi.org/10.4236/wjcs.2022.126009